277 related articles for article (PubMed ID: 21251268)
1. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
BMC Neurol; 2011 Jan; 11():7. PubMed ID: 21251268
[TBL] [Abstract][Full Text] [Related]
2. A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings.
Saldaña MT; Navarro A; Pérez C; Masramón X; Rejas J
Pain Pract; 2010; 10(1):31-41. PubMed ID: 20629966
[TBL] [Abstract][Full Text] [Related]
3. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
[TBL] [Abstract][Full Text] [Related]
4. Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
Pérez C; Navarro A; Saldaña MT; Masramón X; Pérez M; Rejas J
Pain Med; 2013 Dec; 14(12):1954-63. PubMed ID: 24330229
[TBL] [Abstract][Full Text] [Related]
5. Trigeminal neuralgia treated with pregabalin in family medicine settings: its effect on pain alleviation and cost reduction.
Pérez C; Saldaña MT; Navarro A; Martínez S; Rejas J
J Clin Pharmacol; 2009 May; 49(5):582-90. PubMed ID: 19299534
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; Rejas J
Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
[TBL] [Abstract][Full Text] [Related]
7. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
8. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
Saldaña MT; Pérez C; Navarro A; Masramón X; Rejas J
Clin Drug Investig; 2012 Jun; 32(6):401-12. PubMed ID: 22480279
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.
Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
Pain Med; 2010 May; 11(5):719-31. PubMed ID: 20345618
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
13. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
Pérez C; Navarro A; Saldaña MT; Figueras-Balsells M; Muñoz-Tudurí M; Rejas J
Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
[TBL] [Abstract][Full Text] [Related]
14. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; González-Gómez FJ; Ruiz L; Rejas J
Prim Care Diabetes; 2012 Dec; 6(4):303-12. PubMed ID: 22595032
[TBL] [Abstract][Full Text] [Related]
16. A cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish setting.
Prettyjohns M; Sandelin R; Lister S; Norrefalk JR
J Med Econ; 2012; 15(6):1097-109. PubMed ID: 22712872
[TBL] [Abstract][Full Text] [Related]
17. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
Gordon J; Lister S; Prettyjohns M; McEwan P; Tetlow A; Gabriel Z
J Med Econ; 2012; 15(2):207-18. PubMed ID: 22017236
[TBL] [Abstract][Full Text] [Related]
18. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
Athanasakis K; Petrakis I; Karampli E; Vitsou E; Lyras L; Kyriopoulos J
BMC Neurol; 2013 Jun; 13():56. PubMed ID: 23731598
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.
Saldaña MT; Navarro A; Pérez C; Masramón X; Rejas J
Rheumatol Int; 2010 Jun; 30(8):1005-15. PubMed ID: 19798503
[TBL] [Abstract][Full Text] [Related]
20. A cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinics.
Morera-Domínguez C; Ceberio-Balda F; Flórez-García M; Masramón X; López-Gómez V
Clin Drug Investig; 2010; 30(8):517-31. PubMed ID: 20513162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
